Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NKPGU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
EDB- (H16-K222R)-AcLys-vc-CPI-8314
|
|||||
| Synonyms |
EDB- (H16-K222R)-AcLys-vc-CPI-8314
Click to Show/Hide
|
|||||
| Organization |
Pfizer Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
EDB- (H16-K222R)-AcLys
|
Antibody Info | ||||
| Antigen Name |
Vesicle-associated membrane protein 8 (VAMP8)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 34 ng/mL | Positive EDB expression (EDB+++/++) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.9 (IDBS)
|
||||
| In Vitro Model | Normal | WI38-VA13 cells | CVCL_2759 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3449 ng/mL | Negative EDB expression (EDB-) | ||
| Method Description |
Calculated using four-parameter logistic model #203 with XLfit v4.10 (IDBS)
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||